Arrowstreet Capital’s Arcturus Therapeutics ARCT Stock Holding History

Arrowstreet Capital’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-552,179	Closed	-$10.2M	–	1824
2025 Q3	$10.2M	Buy	552,179 +514,652	+1,371%	+$8.27M	0.01%	947
2025 Q2	$488K	Buy	+37,527	New	+$444K	﹤0.01%	1753
2024 Q2	–	Sell	-116,797	Closed	-$3.94M	–	1511
2024 Q1	$3.94M	Buy	116,797 +95,221	+441%	+$3.37M	﹤0.01%	963
2023 Q4	$680K	Buy	+21,576	New	+$513K	﹤0.01%	1175
2023 Q3	–	Sell	-127,244	Closed	-$3.65M	–	1241
2023 Q2	$3.65M	Buy	+127,244	New	+$3.46M	﹤0.01%	693

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Arrowstreet Capital's ARCT Position: Q4 2025 in Review

Arrowstreet Capital sold out of Arcturus Therapeutics (ARCT) in Q4 2025, closing a stake of 552,179 shares — an estimated $10.2M sold.

Arrowstreet Capital first reported a position in ARCT in Q2 2023 and held it in 5 quarters. The position peaked at $10.2M in Q3 2025. 120 funds tracked by Wall St. Rank hold ARCT as of Q4 2025.

Arrowstreet Capital reported no remaining Arcturus Therapeutics position as of Q4 2025 after selling out during the quarter.
Arrowstreet Capital sold 552,179 Arcturus Therapeutics shares in Q4 2025, an estimated $10.2M.
Arrowstreet Capital first reported a position in Arcturus Therapeutics in Q2 2023 and held it in 5 quarters.
Arrowstreet Capital's Arcturus Therapeutics position peaked at $10.2M in Q3 2025.
120 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2025.

Based on Arrowstreet Capital's 13F filing for Q4 2025, filed 13 Feb 2026.